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To rapidly describe the epidemiology of inﬂ  uenza-like 
illness (ILI) during the 2009 winter epidemic of pandemic 
(H1N1) 2009 virus in New South Wales, Australia, we used 
results of a continuous population health survey. During 
July–September 2009, ILI was experienced by 23% of 
the population. Among these persons, 51% were unable 
to undertake normal duties for <3 days, 55% sought care 
at a general practice, and 5% went to a hospital. Factors 
independently associated with ILI were younger age, 
daily smoking, and obesity. Effectiveness of prepandemic 
seasonal vaccine was ≈20%. The high prevalence of risk 
factors associated with a substantially increased risk for ILI 
deserves greater recognition.
D
uring winter 2009, Australia experienced a strong 
inﬂ  uenza epidemic, caused by the pandemic (H1N1) 
2009 virus. In New South Wales (NSW), the most populous 
state of Australia (≈7 million persons), the epidemic lasted 
from late June through early September (1). Despite 
intense surveillance and response efforts, determining the 
epidemiology of inﬂ  uenza at the whole-population level 
remains difﬁ  cult, and considerable uncertainty about the 
disease remains because only a small proportion of infected 
persons are tested (2).
Survey methods have been infrequently used to assess 
the epidemiology of pandemic inﬂ  uenza virus infection 
in the general population. In 1919, a personal household 
interview survey using a sample of population census 
districts from large population centers was used to assess 
illness associated with the ﬁ  rst wave of pandemic inﬂ  uenza 
in the Unites States. Persons called intelligent inspectors 
determined whether the household member was “sick 
since September 1, 1918, with inﬂ  uenza, pneumonia, or 
indeﬁ  nitely diagnosed illness suspected to be inﬂ  uenza.” 
The survey demonstrated substantial demographic, 
geographic, and socioeconomic variation in the apparent 
attack rate of inﬂ  uenza. Expressed as a percentage, the 
overall incidence rate of clinical infection was estimated 
to be ≈28% during the ﬁ  rst wave. The incidence rate was 
≈35% in children and declined with age to ≈30% in adults 
<35 years of age and to ≈10% in persons >75 years of age. 
Incidence was higher among women 15–35 years of age 
than among men in the same age group (3,4).
During the ﬁ  rst epidemic wave of pandemic (H1N1) 
2009, we used a continuous population health survey to 
better understand the epidemiology of the inﬂ  uenza (H1N1) 
virus in the general community. This situation also created 
an unprecedented opportunity to assess the prevalence of 
seasonal inﬂ  uenza vaccination among persons of all age 
groups in our population and its effectiveness against ILI 
during pandemic (H1N1) 2009.
Methods
Since 2002, the NSW Population Health Survey has 
been operating continuously to provide monthly estimates 
of health status and risk factors. The survey involves 
computer-assisted telephone interviews of a randomly 
selected member of randomly selected households. The 
target population is state residents in private households 
with private telephones. The sample is selected by using 
telephone number ranges obtained from an electronic 
telephone book that has been geocoded (spatial coordinates 
assigned to addresses) and stratiﬁ  ed by 8 regional health 
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service boundaries within the state. List-assisted random-
digit dialing is then used to contact households. The target 
sample is ≈1,500 persons per regional health service per 
year, which equals 12,000 persons per year for the state. The 
survey covers all age groups, and interviews for children 
<16 years of age are reported by a parent or caregiver. Full 
details of sample selection and procedures are provided by 
Barr et al. (5). The survey has been approved by the NSW 
Population Health and Health Services Research Ethics 
Committee.
When circulation of pandemic (H1N1) 2009 virus in 
NSW became apparent, ethics approval was obtained to 
add supplementary questions to the survey to determine the 
incidence of inﬂ  uenza–like illness in the population and 
associated health care–seeking behavior and absence from 
normal duties; these questions were added on July 19, 2009. 
The questions were as follows: “In the last 4 weeks, did you 
have an illness with any of the following symptoms: fever 
or high temperature, cough, sore throat, runny nose, fatigue, 
chills or shakes, body aches and pains, shortness of breath, 
the ﬂ  u or ﬂ  u–like symptoms?” Responses were recorded 
for each sign or symptom. Respondents answering “yes” 
to any sign or symptom were asked the following: “Did 
you see a GP for this illness?”; “Did you go to a hospital or 
emergency department for this illness?”; and “How many 
days were you unable to work, study, or manage day-to-
day activities because of the illness?” At the same time, 
we extended the age range for respondents routinely asked 
whether they had been “vaccinated or immunized against 
ﬂ  u in the past 12 months” to persons >6 months of age. 
Previously, the question had been asked only of persons 
>50 years of age. The extended age range would enable 
assessment of vaccine effectiveness against ILI.
We deﬁ   ned ILI as self–reported fever or high 
temperature with cough and fatigue. In a range of general 
practice surveillance systems for seasonal inﬂ  uenza  in 
Australia, this deﬁ  nition performed better than alternative 
deﬁ  nitions; positive predictive value was 23%–60% and 
negative predictive value was 64%–91% (6).
To obtain monthly estimates of ILI incidence, for any 
respondents reporting a symptom in the past 4 weeks we 
assigned their illness to the middle of the reference period, 
that is, 14 days before the interview date. This illness date 
was then assigned to a month of illness.
Answers to other questions routinely asked in the 
survey enabled analysis of additional factors that might be 
associated with ILI reporting (7), including age (0–15, 16–
34, 35–49, 50–64, or >65 years); sex; household size (1–2 
or >3 residents); number of children in household (<2 or 
>2); urban or rural location of residence; socioeconomic 
disadvantage at respondent’s residential postal code, 
which is derived from the Australian Census and takes 
into account income, education, occupation, employment 
status, indigenous status, housing, and other variables 
(index of relative socioeconomic disadvantage [8]: lowest 
2 quintiles = disadvantaged and upper 3 quintiles = not 
disadvantaged); current asthma (respondents >2 years 
of age, diagnosis made by a doctor, and symptoms or 
treatment in the past 12 months); nongestational diabetes 
or high blood glucose status (>9 years, diagnosis made by a 
doctor); smoking status of persons >16 years of age (daily 
smoker, occasional smoker, ex-smoker, or nonsmoker); 
body mass index ([BMI] [weight in kilograms]/[height in 
meters]2) of persons >2 years of age (>30 = obese, 25 to 
<30 = overweight, and <25 = healthy or underweight); 
alcohol drinking at levels associated with health risk 
(>2 Australian standard drinks [1 standard drink = 10 g 
alcohol] on any day) (9); adequate physical activity for 
persons >16 years of age (at least 150 minutes exercising 
per week on >5 occasions, adequate or not adequate), 
psychological distress score for persons >16 years of age 
(Kessler–10 scale ([10] high or very high [score >22], 
moderate, or low); and vaccinated against pneumococcal 
disease in the past 5 years for persons >50 years of age 
(yes or no).
As is standard for household population surveys, the 
data record for each survey respondent was assigned a 
numeric weighting, which was used in all analyses to scale 
their results to the total NSW population. The weighting 
value takes into account the probability (by age, sex, and 
geographic region) of being selected for participation in 
the survey (5). Regression models were used to obtain the 
relative risk (RR) of reporting ILI for each of the factors 
listed in the previous paragraph. The dependent variable for 
each model was ILI, which was assigned 1 of 2 values: 1 if 
the respondent met the criteria for ILI and 0 otherwise. The 
independent variables were >1 factor.
Our modeling strategy was to individually test the 
association between each factor and ILI by using a regression 
model and then to develop a ﬁ  nal model incorporating 
multiple factors to assess whether independent associations 
remained. Because age was strongly associated with ILI, 
we included it as an independent variable in the model for 
all single-factor assessments. Factors with p<0.1 for an 
individual association were included in the ﬁ  nal model. 
Despite its nonsigniﬁ   cance, sex was included in the 
ﬁ  nal model because the prevalence of risk factors in our 
population was known to differ by sex.
To estimate RRs from survey data instead of the more 
usual odds ratios, we used Poisson regression analysis 
with robust variance estimation. RRs were calculated by 
using the GENMOD procedure included in SAS Statistical 
Analysis Software version 9.1.3 for Windows (Cary, 
NC, USA) with the following programming statements: 
a model statement with options dist = Poisson and 
link = log; a class statement including the unique survey 
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respondent number variable; a repeated statement with 
an independent correlation structure (corr = ind) and 
specifying the unique survey respondent number variable 
as the subject parameter; and a weight statement specifying 
the respondent sample weighting normalized to sum to the 
total sample size (11–13). Because the Poisson model uses 
the natural logarithm as the link function, exponentiation 
of the parameter estimates was used to obtain the RR for 
the study factors.
Vaccine effectiveness for ILI was estimated by 1–
RR. RR was the age-adjusted relative risk of reporting 
ILI among respondents reporting seasonal inﬂ  uenza 
vaccination in the past 12 months relative to that for 
unvaccinated respondents. RRs were obtained from the 
regression analysis (14).
Results
Incidence of ILI
From July 19 through October 14, 2009, completed 
interviews were obtained from 2,909 respondents from 
5,017 eligible households contacted during that period. 
Participation rate was 58.0%.
During July 2009, estimated ILI incidence was 12.1% 
(95% conﬁ  dence interval [CI] 9.1%–15.0%), representing 
850,000 (95% CI 640,000–1,060,000) persons (Table 
1). Incidence declined to 7.4% (95% CI 5.3%–9.5%) in 
August, and 3.6% (95% CI 1.2%–5.9%) in September. 
Assuming that during the 3-month window each person 
could only experience ILI 1 time, the monthly incidence can 
be summed to provide an estimate of the total proportion 
of the population experiencing ILI during that period. This 
calculation indicated that an estimated 23.1% (95% CI 
18.8%–59.9%) of the NSW population, or 1,630,000 (95% 
CI 1,330,000–4,240,000) persons, experienced ILI during 
that period.
The only signiﬁ  cant difference was the low incidence 
for persons >65 years of age (5.1%; 95% CI 2.4%–7.9%), 
compared with estimates of 19.1% (95% CI 11.9%–26.2%) 
for those 50–64 years of age and 33.3% (95% CI 24.7%–
42.0%) for those 0–15 years of age (Table 2). Estimates 
were higher for female than male respondents and for 
residents of rural areas, but these differences were not 
signiﬁ  cant.
Outcome of ILI
Inability to undertake normal duties for <3 days was 
reported by approximately half (51%, 95% CI 41%–61%) 
of those reporting ILI (Table 3). Another 12% (95% CI 
6%–18%) were unable to continue their usual duties for 
at least 7 days. Approximately half (55%) sought care at 
a general practice (95% CI 46% – 65%), and 5% (95% CI 
1%–9%) sought care at a hospital.
Prevalence of Seasonal Inﬂ  uenza Vaccination
When we calculated prevalence of seasonal inﬂ  uenza 
vaccination for all age groups, we found that one quarter 
(25%, 95% CI 23%–28%) had been vaccinated against 
inﬂ  uenza in the previous 12 months. The proportion was 
highest among persons >65 years of age (74%, 95% CI 
71%–78%), fell to 33% (95% CI 29%–38%) among those 
50–64 years, and was <20% among those <50 years (Table 
4). Previous estimates in NSW were based on persons >50 
years of age because national immunization policy focused 
on this age group.
Factors Associated with Reporting ILI
Younger age was strongly associated with ILI (Table 
5), which was ≈6× more likely to be reported for children 
<15 years of age than for persons >65 years of age. 
Therefore, for evaluation of all other individual factors, 
we adjusted for age. Only obesity and daily smoking were 
positively associated with reporting ILI. All remaining 
factors showed no signiﬁ   cant association. In the ﬁ  nal 
regression model, we included age, sex, BMI, and smoking 
status. Although sex was not associated with ILI, obesity 
and smoking in our population varied substantially by sex 
and were included in the model. Only persons >16 years of 
age were included because 16 years was the youngest age 
for which smoking questions were asked.
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Table 1. Influenza-like illness cases, by time period, New South 
Wales, Australia, July–September 2009*  
Period
Estimated no., 
millions 
Estimated incidence, % 
(95% CI) 
July  0.85 (0.64–1.06)  12.1 (9.1–15.0) 
August 0.52 (0.38–0.67)  7.4 (5.3–9.5) 
September  0.25 (0.09–0.42)  3.6 (1.2–5.9) 
July–September  1.63 (1.33–1.94)  23.1 (18.8–27.4) 
*Data from 2,909 New South Wales Population Health Survey 
respondents. Influenza-like illness defined as fever with cough and fatigue. 
CI, confidence interval. 
Table 2. Influenza–like illness incidence, New South Wales, 
Australia, July–September 2009*  
Group  Incidence, % (95% CI) 
Sex
 M  19.5 (13.8–25.2) 
 F  26.9 (20.4–33.4) 
Age group, y 
 0–15  33.3 (24.7–42.0) 
 16–34  27.6 (15.6–39.6) 
 35–49  21.3 (13.9–28.8) 
 50–64  19.1 (11.9–26.2) 
 >65 5.1 (2.4–7.9) 
Region 
 Urban  22.3 (16.8–27.8) 
 Rural  26.2 (18.4–34.0) 
*Data from 2,909 New South Wales Population Health Survey 
respondents. Influenza-like illness defined as fever with cough and fatigue. 
CI, confidence interval. Pandemic (H1N1) 2009, New South Wales, Australia
The association with younger age remained in the 
ﬁ  nal model (Table 6). Among the 13.0% (95% CI 10.8%–
15.1%) of the population >16 years of age who reported 
daily smoking, the risk for ILI was 90% (95% CI 10%–
226%) higher than that for less frequent smokers and 
nonsmokers combined. Among the 18.0% (95% CI 15.9%–
20.1%) whose BMI was in the obese category, the risk for 
ILI was 132% (95% CI 30%–316%) greater than that for 
the combined group of persons whose BMI was healthy or 
underweight.
Effectiveness of Seasonal Inﬂ  uenza Vaccine
When the age-adjusted RR for ILI among persons 
reporting vaccination with the seasonal inﬂ  uenza vaccine 
in the past 12 months was used, the estimated vaccine 
effectiveness was 20.0% (95% CI –30.5% to 51.0%), 
indicating a possibly mild but nonsigniﬁ  cant  beneﬁ  t. 
Analysis of effectiveness in speciﬁ  c age groups and by 
sex, region, smoking status, or obesity did not indicate any 
signiﬁ  cant beneﬁ  t (Table 7).
Discussion
In NSW, during the ﬁ  rst Southern Hemisphere winter 
in which pandemic (H1N1) 2009 virus was circulating, at 
least one quarter of the population and one third of children 
experienced ILI. Many infections other than inﬂ  uenza 
can cause ILI (15,16); however, this study was conducted 
during the peak months of the epidemic in NSW, when 
the predictive value of ILI for inﬂ  uenza infection would 
be optimal (6). The epidemic was recognized in Australia 
after mid-June and grew rapidly (1). We were able to obtain 
full monthly estimates of ILI from July only. Late June 
was part of the recall period of the survey questions for 
respondents interviewed in July, and some of that activity 
may have been included in the July estimate.
ILI incidence was similar in urban and rural regions 
and in each sex. Approximately half the persons who 
reported ILI had to limit their usual activities for <4 days. 
Approximately half sought care for their illness at a general 
practice, and 5% sought care at a hospital. Vaccination 
against seasonal inﬂ  uenza did not protect against ILI. Daily 
smoking and obesity each independently doubled the risk 
for ILI.
Consistent with the known epidemiology of pandemic 
(H1N1) 2009 virus infection (1,17–19), incidence of 
ILI decreased with age; the decline was sharp for those 
>65 years of age. The age-speciﬁ   c estimates of ILI 
incidence in NSW in 2009 were remarkably similar to 
those reported during the 1918 inﬂ  uenza pandemic in the 
United States (4). Our overall estimate of an ILI rate of 
23% was higher than the overall population infection rate 
for pandemic (H1N1) 2009 of 16% estimated by a recent 
seroprevalence study from NSW (20). Although the CIs of 
both estimates overlapped and thus the estimates did not 
differ signiﬁ  cantly, explanations for our higher estimate 
could be as follows: 1) some of the ILI in our study was 
caused by other inﬂ  uenza strains that circulated earlier in 
the season (1) and by pathogens other than inﬂ  uenza; 2) 
our study included information collected through the end 
of September, whereas the seroprevalence study included 
some specimens collected before the end of the epidemic 
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Table 3. Illness outcomes for persons reported influenza–like illness, New South Wales, Australia, July–September 2009* 
Outcome  Estimated no. persons, millions (95% CI)†  Proportion, % (95% CI) 
No. days unable to do usual activities 
  0–3  0.83 (0.67–1.00)  51.3 (41.4–61.1) 
  4–7  0.60 (0.44–0.76)  36.7 (26.9–46.5) 
  >7  0.20 (0.09–0.30)  12.0 (5.7–18.4) 
Type of health care sought 
  General practice   0.90 (0.74–1.06)  55.4 (45.5-65.2) 
  Hospital  0.08 (0.02–0.15  5.2 (1.3–9.2) 
  General practice and hospital‡  0.04 (0.01–0.07  2.3 (0.5–4.1) 
  Neither general practice nor hospital  0.68 (0.53–0.83)  41.7 (32.3–51.1) 
*CI, confidence interval.  
†The estimated numbers were obtained by applying the proportions and 95% CIs in this table to the estimated 1.63 million persons with influenza–like 
illness (Table 1). Standard errors of that estimate were ignored. 
‡Because this category overlaps the 2 categories above, total is not 100%. 
Table 4. Prevalence of seasonal influenza vaccination in past 12 
months, New South Wales, Australia, July–September 2009* 
Group  Prevalence, % (95% CI) 
Total NSW population  25.4 (23.3–27.5) 
Sex
 M  24.6 (21.3–27.9 
 F  26.3 (23.7–28.8 
Age, y 
 0–15  11.5 (7.5–15.5) 
 16–34  14.8 (10.2–19.3 
 35–49  16.0 (11.7–20.2 
 50–64  33.2 (29.0–37.5) 
 > 65 74.3 (70.7–77.9 
Region 
 Urban  24.7 (22.1–27.3) 
 Rural  27.2 (23.7–30.7) 
*Data from 2,909 total New South Wales Population Health Survey 
respondents. CI, confidence interval; NSW, New South Wales. RESEARCH
during August; and 3) population samples differed. 
However, the seroprevalence study detected mild and 
asymptomatic infections. Because the seroprevalence 
study used specimens requested from clinical chemistry 
laboratories without randomization, statistical biases may 
arise from the nonrandom sample selection and the disease 
factors leading to a clinical specimen being required. Age-
speciﬁ  c comparisons between the 2 studies were broadly 
consistent. Serosurvey infection rate estimates were 10%–
35% among children, 24% among adults 18–34 years 
of age, 20% among adults 35–64 years of age, and no 
infection among older adults. Our estimates for ILI were 
33% among children, 28% among persons 16–34 years of 
age, 20% among adults 35–64 years of age, and 5% among 
older adults. The seroprevalence study estimated reduced 
infection rates outside the urban state capital of Sydney; 
our study found similar incidence rates in urban and rural 
areas.
Other studies that assessed household size and risk for 
transmission found mixed results: some found increased 
risk (21,22) and another found decreased risk (23) with 
increasing household size. A higher number of children 
in a household has also been identiﬁ  ed as a risk factor for 
inﬂ  uenza transmission in households (24). However, our 
ﬁ   nding of no association with either household size or 
number of children in the household is consistent with the 
result of household transmission studies of the pandemic 
2009 (H1N1) virus (18,25) and with results of another study 
of ILI among children during seasonal inﬂ  uenza season in 
Australia (26). This lack of effect may reﬂ  ect  improved 
living standards in this country.
The lack of protection from recent seasonal inﬂ  uenza 
vaccination has been reported elsewhere (18,27,28), but a 
study in Mexico found partial protection (29). The subtype 
H1N1 component of the Northern and Southern Hemisphere 
vaccines at that time was the same: A/Brisbane/59/2007–like.
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Table 5. Risk factors evaluated for influenza-like illness, New South Wales, Australia, July–September 2009* 
Factor 
Factor prevalence, 
% (95% CI)  Reference category† 
Age group analyzed 
(no. respondents)‡ 
Relative risk  
(95% CI)  p value§
Age, y  >65 y  All ages (2,909) 
 0–15  21.4  (19.4–23.5)  5.96  (3.25–10.93)  <0.001
 16–34  26.0  (23.2–28.8)  4.76  (2.35–9.62)  <0.001
 35–49  21.7  (19.4–23.9)  3.55  (1.86–6.79)  <0.001
 50–64  17.7  (16.1–19.3)  3.00  (1.57–5.71)  0.001
Female sex¶   50.5 (47.8–53.2)  Male All ages (2,909)  1.31 (0.89–1.94)  0.173 
Rural region¶   29.9 (28.4–31.4)  Urban  All ages (2,909)  1.26 (0.87–1.84)  0.227 
Socioeconomically 
disadvantaged¶ # 
38.4 (35.9–40.9)  Not disadvantaged  All ages (2,909)  0.93 (0.63–1.38)  0.729 
>2 children in household¶   34.5 (31.9–37.2)  <2 children residing in 
household
All ages (2,909)  0.75 (0.51–1.10)  0.142 
>3 persons in household¶   67.7 (65.6–69.7)  1–2 persons in household  All ages (2,909)  1.14 (0.75–1.72)  0.536 
Seasonal influenza 
vaccination in past 12 mo¶  
25.6 (23.5–27.7)  No seasonal influenza 
vaccination in past 12 mo 
>6 mo (2,888)  0.80 (0.49–1.31)  0.372 
Current asthma¶   11.4 (9.8–13.0)  No current asthma  >2 y (2,831)  1.15 (0.69–1.92)  0.595 
Body mass index¶   >2 y (2,831) 
  Obese  18.0 (15.9–20.1)  Healthy or underweight  2.14 (1.31–3.48)  0.002 
  Overweight  28.6 (26.3–31.0)  Healthy or underweight  1.06 (0.67–1.67)  0.816 
Current diabetes or high 
blood glucose¶
8.0 (6.7–9.2)  No current diabetes or high 
blood glucose 
>9 y (2,636)  0.97 (0.50–1.91)  0.936 
Daily smoker¶   13.0 (10.8–15.1)  Occasional/ex-/non-smoker  >16 y (2,431)  1.94 (1.06–3.54)  0.031 
Inadequate physical 
activity¶  
48.6 (45.6–51.7)  Adequate physical activity  >16 y (2,431)  1.04 (0.65–1.65)  0.881 
Risky alcohol drinking¶   31.6 (28.6–34.7)  Low-risk alcohol drinking  >16 y (2,431)  1.25 (0.76–2.05)  0.378 
High or very high 
psychological distress 
score¶  
11.2 (9.4–13.1)  Moderate or low 
psychological distress score
>16 y (2,431)  1.41 (0.85–2.35)  0.182 
Pneumococcal vaccination 
in past 5 y¶  
28.3 (25.7–30.9)  No pneumococcal 
vaccination in the past 5 y 
(adjusted for age) 
>50 y (1,633)  1.20 (0.56–2.56)  0.640 
*CI, confidence interval. 
†Not stated and “Don’t know” responses were included in the reference category. Among parameters with any such responses, the proportions were 
index of socioeconomic disadvantage 0.9%, vaccinated against influenza in the past 12 mo 1.0%, current asthma 0.3%, body mass index 5.2%, smoking 
status 0.1%, psychological distress score 3.0%, alcohol use 1%, and pneumococcal vaccination 7.0%. 
‡Some questions are only collected on selected age groups, so sample sizes vary. 
§Significant results at the 5% level are in boldface.
¶Adjusted for age. 
#Disadvantaged = lowest 2 quintiles of the Australian index of relative socioeconomic disadvantage based on the respondent's residential postcode; not 
disadvantaged = upper 3 quintiles. Pandemic (H1N1) 2009, New South Wales, Australia
Obesity and smoking are 2 preventable risk factors 
we found to be strongly associated with ILI. Smoking has 
been frequently identiﬁ  ed as a risk factor for inﬂ  uenza; 
the identiﬁ  ed mechanisms are mechanical, structural, and 
immunity related (30–32). Although obesity has been 
frequently identiﬁ  ed as a risk factor for severe outcomes 
of infection with pandemic 2009 (H1N1) virus (33–35), 
it has not been previously recognized as a risk factor 
for susceptibility to symptomatic inﬂ   uenza infection in 
humans. A recent study in mice found that an immune 
memory response to recent inﬂ  uenza infection was reduced 
among obese mice; this reduced memory led to more severe 
disease, lung pathology, and virus titers after a second 
exposure to the same mouse-adapted inﬂ  uenza strain (36).
In addition to possibly excluding the early part of the 
epidemic, our study has other limitations. Inﬂ  uenza  in 
respondents was not conﬁ  rmed by testing; other common 
winter respiratory viruses, such as respiratory syncytial 
virus, can cause a similar syndrome (16). General practice 
surveillance in various regions of Australia, conducted 
during circulation of seasonal inﬂ  uenza virus, indicated that 
the syndrome deﬁ  nition we used had a positive predictive 
value of 23%–60% (6). Although these values are not high, 
positive predictive value is probably increased during a 
larger than usual epidemic (37). Pandemic concern may 
have prompted more persons than usual to get vaccinated 
for seasonal inﬂ  uenza. This concern and response would 
produce higher vaccination prevalence in our study than 
would have occurred in the absence of a pandemic. Evidence 
shows that publicity prompted increased vaccination among 
persons >65 years of age, from 68% in April 2009 to 77% in 
May 2009. Prevalence remained higher for several months 
(38). In our study, we were unable to include 2 frequently 
reported risk factors for poor outcomes of pandemic 
(H1N1) 2009 virus infection: pregnancy and indigenous 
status (39,40). Although indigenous status is included in 
the health survey, the number of Aboriginal and pregnant 
respondents in the period of time covered would be too 
small to obtain usable estimates for these risk factors.
Conclusions
When pandemic (H1N1) 2009 virus was circulating in 
the NSW population, ILI was experienced by at least one 
quarter of the population. Recent prepandemic seasonal 
vaccination was not protective. Although smoking is already 
known to increase susceptibility to inﬂ  uenza  infection, 
obesity is not. The role of obesity in susceptibility needs 
further evaluation in studies in which inﬂ  uenza infection 
can be conﬁ  rmed. The high prevalence of these preventable 
risk factors in our population, combined with a substantially 
increased risk for ILI, deserves greater recognition. 
Using an established health survey for monitoring ILI is 
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Table 6. Final model of factors associated with reporting influenza-like illness, New South Wales, Australia, July–September 2009*
Factor, n = 2,431 respondents 
Prevalence of factor, % 
(95% CI)  Reference category†  Relative risk (95% CI)  p value‡ 
Age, y  >65 y
  16–34  26.0 (23.2–28.8)  4.74 (2.38–9.45)  <0.001
  35–49  21.7 (19.4–23.9)  3.25 (1.68–6.26)  <0.001
  50–64  17.7 (16.1–19.3)  2.60 (1.36–4.99)  0.004
Female sex  50.5 (47.8–53.2)  Male 1.25 (0.76–2.05)  0.375 
Daily smoker   13.0 (10.8–15.1)  Occasional/ex-/nonsmoker  1.90 (1.10–3.26)  0.021
Body mass index 
  Obese  18.0 (15.9–20.1)  Healthy or underweight  2.32 (1.30–4.16)  0.005
  Overweight  28.6 (26.3–31.0)  Healthy or underweight  1.20 (0.68–2.12)  0.534 
*Influenza-like illness defined as fever with cough and fatigue. Some questions are only collected on selected age groups, so sample sizes vary. CI, 
confidence interval. 
†Not stated and “Don’t know” responses were included in the reference category. Among parameters with any such responses, the proportions were body 
mass index 5.2%; smoking status 0.1%. 
‡Statistically significant results at the 5% level are in boldface.
Table 7. Effectiveness of seasonal influenza vaccine against 
influenza-like illness, New South Wales, Australia, July–
September 2009*  
Subgroup, n = 2,888  Vaccine effectiveness, % (95% CI)† 
Age, y 
 0.5–15  6.1 120.1 to 60.0) 
 16–34  44.6 166.8 to 88.5) 
 35–49  0.9 137.2 to 57.1) 
 50–64  33.7 69.7 to 74.1) 
 >65 97.9 622.5 to 45.8) 
Sex† 
 M  34.5 71.7 to 75.0) 
 F  10.5 49.2 to 46.4) 
Region† 
 Urban  17.1 55.7 to 55.9) 
 Rural  25.5 49.7 to 62.9) 
Smoking status† 
 Daily  smoker  1.4 175.3 to 64.7) 
  Not daily smoker  22.3 53.2 to 60.6) 
Body mass index† 
 Obese  25.0 81.6 to 69.1) 
 Not  obese  9.2 66.0 to 50.4) 
Overall† 20.0 30.5 to 51.0) 
*For persons >6 mo of age vaccinated in past 12 mo.  CI, confidence 
interval. 
†Adjusted for age. RESEARCH
inexpensive and provides an opportunity to assess a broad 
range of risk factors. Continued monitoring will enable 
better assessment of the value of survey-based inﬂ  uenza 
surveillance through comparison with other inﬂ  uenza and 
respiratory illness surveillance systems and can provide 
continuous assessment of risk factors for ILI.
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